AtheroGenics (AGIX) Cuts Headcount by 40%; to Record One-Time Charge of $400K in Q3
More News related to AGIX
- AtheroGenics (AGIX) Cuts Headcount by 40%; to Record One-Time Charge of $400K in Q3
- AtheroGenics (AGIX) Receives Delisting Notification From NASDAQ
- Pre-Open Movers 4/14: Circuit City (CC) Surges on Blockbuster Bid, Wachovia (WB) Sinks on Losses/Capital Raise
- AtheroGenics (AGIX) Reports Positive Preliminary Results from Phase 3 Trial of ANDES
- Unusual 11 Mid-Day Movers 3/4: STEN, LF, PRAN, FINL Higher; TSRA, OMPI, JTX, THRX Lower
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
In a Form 8-K, AtheroGenics, Inc. (Nasdaq: AGIX) announced that on September 19, the company reduced its employee headcount by approximately 40% to a current staff of 30 employees. In addition, the Company has also eliminated approximately 20 open positions as a result of the downsizing. The Company is providing severance to employees affected by the workforce reduction, resulting in a one-time charge of approximately $400,000 related to the severance benefits, which will be paid in Q308.
Atherogenics Inc., a research-based pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
